{"url_path":"/sec/ktta/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","accession_number":"0001213900-26-057837","cik":"0001841330","ticker":"KTTA","issuer_name":"Pasithea Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","primary_entity_key":"0001841330","primary_entity_name":"Pasithea Therapeutics Corp."},"word_count":58,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n \n\n(a)\nNone.\n\n \n\n(b)\nNone.\n\n \n\n(c) During the fiscal quarter ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(c) of Regulation S-K.\n\n \n\n30"}